Skip to main
SMTI
SMTI logo

SMTI Stock Forecast & Price Target

SMTI Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Sanara MedTech Inc has demonstrated strong revenue growth, with a notable 28% year-over-year increase in its soft tissue repair products, particularly driven by higher demand for its CellerateRX Surgical Activated Collagen. Furthermore, the company has achieved a 25% year-over-year growth in its bone fusion products, indicating a robust performance across its product segments. With a strategic focus on expanding distribution partnerships and increasing penetration in healthcare facilities, the company is well-positioned to sustain topline growth in the coming year.

Bears say

Sanara MedTech faces significant risks that may adversely affect its financial performance, including lower-than-projected revenue growth and challenges in securing additional customers. The company also encounters obstacles regarding the successful launch of new products or services, which could hinder its market competitiveness. Additionally, potential dilution risk poses a further threat to shareholder value and overall investment viability.

SMTI has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sanara MedTech Inc. (SMTI) Forecast

Analysts have given SMTI a Buy based on their latest research and market trends.

According to 2 analysts, SMTI has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sanara MedTech Inc. (SMTI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.